Minimal disease activity for rheumatoid arthritis: a preliminary definition

- Wells, G. A., Boers, M., Shea, B., Brooks, P. M., Simon, L. S., Strand, C. V., Aletaha, D., Anderson, J. J., Bombardier, C., Dougados, M., Emery, P., Felson, D. T., Fransen, J., Furst, D. E., Hazes, J. M. W., Johnson, Kent R., Kirwan, J. R., Landewe, R. B. M., Lassere, M. N. D., Michaud, K., Suarez-Almazor, M., Silman, A. J., Smolen, J. S., van der Heijde, Dmfm, van Riel, Plcm, Wolfe, F., Tugwell, P. S.

Standardized assessment of adverse events in rheumatology clinical trials: Summary of the OMERACT 7 Drug Safety Module update

- Lassere, M. N. D., Johnson, Kent R., Boers, M., Carlton, K., Day, R. O., de Wit, M., Edwards, I. R., Fries, J. F., Furst, D. E., Kirwan, J. R., Tugwell, P. S., Woodworth, T. G., Brooks, P. M.